clinical trial · NCT07046273
Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
Shandong New Time Pharmaceutical Co., LTD·phase3·not yet recruiting·n = 496
Type 2 Diabetes (T2DM)F027Ozempic®
brief summary
This study is a multicenter, randomized, open, parallel-controlled, Phase III clinical study aimed to evaluate the efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes.
started
Aug 1, 2025
primary completion
Aug 1, 2028
completion
Feb 1, 2029
last updated
Jul 1, 2025
official title
A Multicenter, Randomized, Open, Parallel-controlled, Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 Diabetes
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol